Press-release for stocks for egrx

Prices are updated after-hours

Licensing Agreement for U.S. Commercial Rights to Landiolol, a Beta-1 Adrenergic Blocker
Published: 2021-09-09 (Crawled : 19:00) - eagleus.com
EGRX | $4.78 5.06% 4.81% 88K

| -91.24% | O: -0.86% H: 1.33% C: 0.38%
license commercialization

Worldwide Licensing Agreement for CAL02 a Phase 2b/3, Novel First-in-Class Antitoxin Agent
Published: 2021-09-09 (Crawled : 19:00) - eagleus.com
EGRX | $4.78 5.06% 4.81% 88K

| -91.24% | O: -0.86% H: 1.33% C: 0.38%
phase 2 phase 2b license

Eagle Pharmaceuticals Wins Vasopressin Patent Trial
Published: 2021-09-09 (Crawled : 19:00) - eagleus.com
EGRX | $4.78 5.06% 4.81% 88K

| -91.24% | O: -0.86% H: 1.33% C: 0.38%
patent trial

78%

22%

MTTR | News 4 | $4.6 164.37% 62.17% 28M

AGBA | $2.94 135.2% 57.48% 66M

EDBL | News | $6.46 71.81% 41.8% 2M

MTC | $2.25 44.23% 30.67% 6M

OPRT | News | $3.175 41.11% 29.13% 12M

SHIM | $3.05 35.56% 26.23% 1.1M

HKIT | $1.345 31.86% 24.16% 390K

ABVC | $1.36 30.77% 23.53% 7.4M

OST | $0.512 28.0% 21.88% 290K

POET | $1.59 27.2% 21.38% 4.2M

Save your searches and get alerts when important news are released.